Fourth Annual Chicago Supportive Oncology Conference

Community Oncology

Volume 3, Number 7 (July 2006)

Letter from the Editor

404

 

The rules of engagement

Lee S. Schwartzberg, MD, FACP, Editor-in-Chief

The West Clinic, Memphis, TN

If you want to know whether we’re winning the war against cancer, you need look no further than the pages of this month’s issue of Community Oncology. In it, we report on the most striking developments against kidney cancer, an illustration of how, for the first time, we can design agents that target central processes in tumor cells. We’re beginning to turn the tide by launching precision raids that disrupt the enemy’s basic structure. This issue also contains several articles on “winning the peace” as well—treating patients and their families holistically, taking into account their special needs and emotions.

full text 45 kb

Community Dialogue

415

 

Championing transparency in clinical trials

Community Oncology interviews Philip A. Pizzo, MD, dean of the School of Medicine at Stanford University.

With nearly one third of scientists surveyed admitting that they might have changed the reporting of their data based on a funding source, it becomes more important than ever to regain public trust in medical research. Dr. Pizzo has made that his mission.

full text 82 kb

Community Translations

419

 

Targeted therapy of renal cell carcinoma

Matt Stenger, MS

Treatment with two recently approved tyrosine kinase inhibitors is offering new hope to patients with metastatic disease. Work on renal cell carcinoma is at the forefront of new targeted therapies and new classes of pharmaceuticals.Because many patients have experienced prolonged stable disease and partial responses, these results may soon call into question the endpoints of clinical trials.

full text 90 kb

422

 

Improving survival of patients with advanced renal cell carcinoma: a new paradigm

Nicholas J. Vogelzang, MD

Nevada Cancer Institute, Las Vegas, NV

full text 92 kb

Challenging Cases/Rare Cancers

428

 

Treatment update for metastatic pancreatic cancer

Maureen R. Hewitt, MD, and Kenneth Yu, MD

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

The treatment of metastatic pancreatic cancer continues to be a major unresolved health problem and a therapeutic challenge, with a poor median survival averaging 3–6 months. Early study results with gemcitabine indicate a potential survival benefit in patients with this disease, illustrated here in a case report of a 75-year-old man who defied the odds.

abstract full text 92 kb

Economics/Practice Management

432

 

Emergency preparedness for cancer clinics—a necessity

Steven M. Coplon, MHA

The West Clinic, Memphis, TN

In the wake of disasters, both man-made and natural, from the horrors of 9/11 to Hurricane Katrina, the need for emergency preparedness has become all too evident. This article compiles practical advice from cancer clinics in eight states on how to respond to seriously disruptive events.

abstract full text 98 kb

Psychosocial Oncology

443

 

Modesty and healthcare for women: understanding cultural sensitivities

Caryn Scheinberg Andrews, PhD, CRNP

Alvin and Lois Lapidus Cancer Institute, Northwest Hospital Center, Randallstown, MD

Across diverse cultures and ethnicities, many women have named modesty as the reason they do not obtain cervical screening or mammography. Based on research that explored and defined modesty among Jewish women from Baltimore, MD, the author presents a series of studies related to modesty and healthcare utilization. Understanding these phenomena, she says, will significantly impact intervention design and treatment practices.

abstract full text 109 kb

Nursing Management

449

 

Educational and emotional support of patients with non-Hodgkin’s lymphoma

Carolyn Hendrix, RN, OCN, BSN, and Cristina de Leon, RN, CRA, BSN

Cancer Outpatient Treatment Clinic, Hoag Cancer Center, Newport Beach, CA, and Hoag Cancer Center, Newport Beach, CA

Patients with non-Hodgkin’s lymphoma experience a roller-coaster ride of care. Nurses can guide these patients through difficult decisions about treatment options during the various stages of the disease and help them become knowledgeable partners in their own care.

abstract full text 88 kb

Controversies in Patient Management

462

 

Strategies for improving end-of-life care

Sally Welsh, MSN, RN, CNAA-BC

Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, GA

By helping patients distinguish between palliative and hospice care and by using a screening tool to identify those who may benefit from a palliative care consultation, community oncologists can dismantle some of the barriers to providing appropriate end-of-life care.

abstract full text 178 kb

Having Your Say

411

 

Prove that community oncologists put patients before profits

Brian Klepper, PhD

Center for Practical Health Reform, Baton Rouge, LA

full text 56 kb

412

 

Good point; here’s what we’re doing

Lee S. Schwartzberg, MD

Community Oncology Alliance, Washington, DC

full text 56 kb

Technology

436

 

Tablet PCs: getting to the heart of the matter

John J. Fried

With tablet PCs asking the time-consuming questions, doctors and nurses can focus on the most important patient issues that need to be addressed during all-too-short office visits.

full text 59 kb

Washington Update

455

 

The pressure is on for full disclosure in clinical trials reporting

Cori Vanchieri

Posting trials data on an independent results database is an “ethical imperative.”

full text 54 kb

456

 

Cancer legislation roundup

Joel B. Finkelstein

The latest cancer-related bills.

full text 46 kb

Legal Matters

467

 

Ask your lawyer: e-mailing patients: how to reduce the legal risks

Lee W. Doty, Esq.

Philadelphia, PA

Strategies to protect your patients and practice.

full text 65 kb

© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.